U · A
Unknown Author
January 24, 2026
Latham Advises Abridge in US$150 Million Investment Round
1 min
AI-made summary
- Abridge, a company specializing in generative AI for clinical documentation, has secured an additional US$150 million investment following rapid adoption of its product by health systems across the United States
- This funding round, which follows a US$30 million Series B four months prior, is among the largest in generative AI for healthcare
- Latham represented Abridge in the transaction, with a team led by partners Brian Patterson, Heather Deixler, and Ghaith Mahmood.
Abridge, the leader in generative AI for clinical documentation, has announced an additional US$150 million investment, leveraging momentum from their product’s rapid uptake among health systems throughout the nation. This raise comes just four months after their US$30M Series B, and is one of the largest funding rounds made to date in generative AI for healthcare. Latham represented Abridge in the investment, with a corporate deal team led by Bay Area partners Brian Patterson and Heather Deixler, and Los Angeles partner Ghaith Mahmood, with associates Ed Grigoryan, Saem Kim, and Nicole Nour.~~
U
Article Author
Unknown Author
The Sponsor